![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JA Qi, JS Heyman, RJ Sheldon, RJ Koslo and F Porreca
Department of Pharmacology, University of Arizona Health Sciences Center, Tucson 85724.
It is now well established that compounds classified as kappa opioids can, in circumstances where they produce no measurable agonist effects, antagonize the actions of mu opioids. Largely on the basis of studies in vitro, beta-funaltrexamine (beta-FNA) has been classified as a reversible kappa agonist and long acting mu antagonist. The present study investigated the possibility that the mu antagonist profile of this compound could be related to its kappa agonist actions. We used two tests of analgesia (the acetic acid writhing test and the hot-water tail-flick test) and selective kappa agonists and antagonists given at supraspinal and spinal sites in mice. Intrathecal (i.t.) administration of beta-FNA, but not the selective kappa agonist U50,488H, produced long-lasting and dose-related analgesia in the writhing test for periods up to 48 hr after a single dose. In contrast, i.t. beta-FNA had no agonist actions in the tail-flick test. The kappa antagonist, nor- binaltorphimine (nor-BNI) produced no agonist effects in either analgesic test when given i.t. In the writhing test, nor-BNI produced a rightward displacement of the beta-FNA dose-response line regardless of whether beta-FNA was given 10 min or 4 hr before testing, indicating that i.t. beta-FNA was acting as a kappa agonist in this test. As both i.t. morphine and beta-FNA are active in the writhing test, the antagonist actions of i.t. beta-FNA could be evaluated only in the tail- flick test. beta-FNA, but not nor-BNI, blocked the effects of i.t. morphine in the tail-flick test.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  A. K. Baker and T. F. Meert Functional Effects of Systemically Administered Agonists and Antagonists of {micro}, delta , and kappa Opioid Receptor Subtypes on Body Temperature in Mice J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1253 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Porreca, S. E. Burgess, L. R. Gardell, T. W. Vanderah, T. P. Malan Jr, M. H. Ossipov, D. A. Lappi, and J. Lai Inhibition of Neuropathic Pain by Selective Ablation of Brainstem Medullary Cells Expressing the {micro}-Opioid Receptor J. Neurosci., July 15, 2001; 21(14): 5281 - 5288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Puig and O. Pol Peripheral Effects of Opioids in a Model of Chronic Intestinal Inflammation in Mice J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1068 - 1075. [Abstract] [Full Text]
|
|
|
|
|
|
R. C. Pitts, R. M. Allen, E. A. Walker, and L. A. Dykstra Clocinnamox Antagonism of the Antinociceptive Effects of Mu Opioids in Squirrel Monkeys J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1197 - 1206. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. O'Neill, M. A. Collins, H. O. Pettit, R. W. McNutt, and K.-J. Chang Antagonistic Modulation Between the Delta Opioid Agonist BW373U86 and the Mu Opioid Agonist Fentanyl in Mice J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 271 - 277. [Abstract] [Full Text]
|
|
|
|
|
|
C. C. Taylor, D. Wu, Y. Soong, J. S. Yee, and H. H. Szeto Opioid Modulation of the Fetal Hypothalamic-Pituitary-Adrenal Axis: The Role of Receptor Subtypes and Route of Administration J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 129 - 135. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
